Abstract
Use of live attenuated influenza vaccines in young children in resource-poor settings.
Highlights
Children younger than 5 years are in the age group most vulnerable to infection with influenza virus, and these infections contribute substantially to the overall harm caused to the general population
Russian-backbone live attenuated influenza vaccines (LAIVs) has a long history of development, and it was a great achievement when this technology was licensed to WHO with permission to grant sublicenses to vaccine manufacturers in newly industrialised and developing countries within the framework of the WHO Influenza Vaccine Technology Transfer Project.[1]
In The Lancet Global Health, two studies are reported by W Abdullah Brooks and colleagues[3] and John C Victor and colleagues[4] that present the safety and efficacy results for an Indian-made Russian-backbone LAIV given to young children in Bangladesh and Senegal
Summary
Children younger than 5 years are in the age group most vulnerable to infection with influenza virus, and these infections contribute substantially to the overall harm caused to the general population. Use of live attenuated influenza vaccines in young children in resource-poor settings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
